Medrad highlights future of CT contrast injectors
Dec. 7 – Medrad displayed its “CT Contrast Injections of the Future” exhibit at the Radiological Society of North America (RSNA) exhibition in Chicago last week.

The CT futures exhibit showed the leading role of contrast injection in CT imaging, patient safety, patient-specific protocol optimization, workflow and data integration innovations that are in development at the Indianola, Pa.-based Medrad.

Cliff Kress, senior vice president of Medrad’s CT division, said the exhibit was designed to provide “a glimpse into concepts still on the drawing board…and the leading role that injection technology will have in the years to come.”

Medrad displayed its Stellant CT injection system that has nearly 10,000 installations throughout the world with enhancements such as DualFlow simultaneous injection and scanner-injector interface technology.

The company also showcased two new additions: CardiacFlow powered by P3T and XDS extravasation detector. CardiacFlow is the first application of MEDRAD’s P3T, personalized patient protocol technology, which uses patient-specific parameters to optimize injection timing and contrast volume, and was designed for cardiac CT imaging procedures. It is FDA 510(k) and patent pending.

The Medrad XDS Extravasation Detector is a patented product designed to prevent moderate to severe contrast extravasations that may seriously injure patients. XDS was U.S. FDA 510(k) cleared in March.